Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer

Journal of Surgical Oncology

Volumn 96, Issue 7, 2007, Pages 605-610

  Nagano, Hideki ^a   Goi, Takanori ^a   Koneri, Kenji ^a   Hirono, Yasuo ^a   Katayama, Kanji ^a   Yamaguchi, Akio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Angiogenesis; Colorectal cancer; Metastasis

Indexed keywords

ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; MESSENGER RNA;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR, ENDOCRINE-GLAND-DERIVED;

EID: 36549077660     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20716     Document Type: Article

References (41)

1. Muto T, Kotake K, Koyama Y: Colorectal cancer statistics in Japan: Data from JSCCR registration, 1974-1993. Int J Clin Oncol 2001;6:171-176.
2. Koyama Y, Kotake K: Overview of colorectal cancer in Japan: Report from the Registry of the Japanese Society for Cancer of the Colon and Rectum. Dis Colon Rectum 1997;40:2-9.
3. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
4. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
5. LeCouter J, Kowalski J, Foster J, et al.: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001;412:877-884.
6. Goi T, Fujioka M, Satoh Y, et al.: Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor. Cancer Res 2004;64:1906-1910.
7. Fleming ID, Cooper JS, Henson DE, et al.: AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven, 1997.
8. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. 1st English edition. Tokyo: Kanehara, 1997.
9. Goi T, Yamaguchi A, Nakagawara G, et al.: Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 1998;77:466-471.
10. Sato T, Yamaguchi A, Goi T: Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004;87:174-181.
11. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
12. Risau W: Mechanisms of angiogenesis. Nature 1997;386:671-674.
13. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micro-metastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
14. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1187.
15. Toi M, Matsumoto T, Bando H: Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667-673.
16. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
17. O'Reilly MS, Holmgren L, Chen C, et al.: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
18. Boehm T, Folkman J, Browder T, et al.: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
19. Harris AL: Antiangiogenesis for cancer therapy. Lancet 1997;349:13-15.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
21. Shibuya M, Yamaguchi S, Yamane A, et al.: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-524.
22. Shibuya M, Ito N, Claesson-Welsh L: Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59-83.
23. Kong HL, Hecht D, Song W, et al.: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9:823-833.
24. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
25. Wedge SR, Ogilvie DJ, Dukes M, et al.: ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970-975.
26. Witty JP, McDonnell S, Newell KJ, et al.: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-4812.
27. Hasegawa S, Koshikawa N, Momiyama N, et al.: Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998;76:812-816.
28. Naglich JG, Jure-Kunkel M, Gupta E, et al.: Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480-8485.
29. Maekawa R, Maki H, Wada T, et al.: Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor. Clin Exp Metastasis 2000;18:61-66.
30. Patterson BC, Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-28825.
31. Yamaguchi A, Urano T, Goi T, et al.: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996;14:1122-1127.
32. Seki K, Yamaguchi A, Goi T, et al.: Inhibition of liver metastasis formation by anti-CD44 variant exon 9 monoclonal antibody. Int J Oncol 1997;11:1257-1261.
33. Akagi K, Ikeda Y, Miyazaki M, et al.: Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000;83:887-891.
34. Seto S, Onodera H, Kaido T, et al.: Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301.
35. Risau W: Mechanisms of angiogenesis. Nature 1997;368:671-674.
36. Yancopoulos GD, Davis S, Gale NW, et al.: Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
37. Kumagai Y, Toi M, Inoue H: Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research. Lancet Oncol 2003;3:604-610.
38. Ichikura T, Tomimatsu S, Ohkura E, et al.: Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001;78:132-137.
39. Toi M, Inada K, Suzuki H, et al.: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
40. Arai N, Strom A, Rafter JJ, et al.: Estrogen receptor beta mRNA in colon cancer cells: Growth effects of estrogen and genistein. Biochem Biophys Res Commun 2000;270:425-431.
41. Gerber HP, Kowalski J, Sherman D, et al.: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-6258.